Artelo Biosciences Inc. (NASDAQ: ARTL) announced it received confirmation from The Nasdaq Stock Market LLC that the company has regained compliance with two key listing requirements.

The pharmaceutical company satisfied Nasdaq Listing Rule 5550(b)(1), known as the "Equity Rule," and Listing Rule 5620(a), the "Annual Shareholders Meeting Rule," according to a letter from the exchange.

Nasdaq confirmed that Artelo held its reconvened annual meeting on January 30, 2026, based on the company's Form 8-K filing from that date. The company regained compliance with the Equity Rule based on a March 30, 2026 Form 8-K filing.

Under Nasdaq Listing Rule 5815(d)(4)(B), Artelo will be subject to a mandatory panel monitor for one year from the date of the compliance letter.

"We are pleased to have regained compliance with Nasdaq's continued listing requirements," said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.

Artelo is a clinical-stage pharmaceutical company developing treatments that modulate lipid-signaling pathways for cancer, pain, dermatological, and neurological conditions. The company is advancing ART27.13 for cancer anorexia-cachexia syndrome and glaucoma, and ART26.12 for neuropathic pain treatment.

The company's drug candidate ART27.13 is being investigated in a Phase 2 study for glaucoma treatment, while ART26.12 represents the first product from Artelo's FABP5 inhibitor platform designed as a non-opioid treatment for neuropathic pain.